July 18, 2019: Anal neoplasia risk amidst comorbid HPV and chlamydia; predictive modeling for PrEP outreach; long-term benefits of hepatitis C cure in coinfection; first-line therapy with dolutegravir/lamivudine.
Will potential study participants choose a vaccine trial over getting access to PrEP?
Next week, 6,000 HIV researchers and experts are expected to make their way to Mexico City for the 10th International AIDS Society Conference on HIV Science, which will feature more than 1,000 abstracts highlighting the latest findings in HIV treatment, prevention, and public health policy.
The US Preventive Services Task Force released its final ruling in *JAMA*.
New York City aims to expand PrEP and PEP access by educating more clinicians that serve women.
A team led by Shannon Weber, M.S.W., has developed PleasePrEPMe, an online PrEP provider search and chat service.
Anthony J. Santella, Dr.P.H., explains why prevention efforts are lagging within the largest suburban HIV epidemic in the U.S.
April 18, 2019: lamivudine/raltegravir for PrEP; feminizing hormone may impact PrEP efficacy; why TAF has a better renal profile than TDF; the role of internet dating in HIV incidence trends.
April 4, 2019: what’s driving the HIV outbreak in northeastern Massachusetts; race-gender HIV disparities among Baltimore sex workers; high PrEP interest, low awareness among southern black women; naltrexone implants for opioid dependence.
Health care providers often believe stereotypes that PWID are irresponsible and won't adhere to PrEP, according to data presented at the 2019 National HIV Prevention Conference.